CSPC Pharmaceutical Group has entered into a contract with AstraZeneca in relation to the establishment of a joint ...
Counterfeit and unauthorised healthcare products remain a persistent risk across Asia, particularly where fragmented dis...
AsymBio, a China-based biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of ...
Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have reported positive Phase IIa results for vortos...
Shanghai Ark Biopharmaceutical, or ArkBio, has completed dosing across all healthy-volunteer cohorts in an Australian Ph...
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration to b...
Antengene has received a $60 million upfront payment from UCB under a worldwide exclusive licensing agreement for ATG-20...
Kelun-Biotech has received approval from the Center for Drug Evaluation of China’s National Medical Products Admin...
Hong Kong headquartered Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discover...
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymche...
A growing burden demands a new approach Cardiac ablation treats AFib by targeting heart cells that send erratic signals...
Harbour BioMed, a US-based biopharmaceutical company, has entered into a strategic collaboration with China Nationa...
Takeda China has announced that the National Medical Products Administration (NMPA) has approved the use of ORZEYFUL (ov...
It is estimated that by 2040 China-originated treatments will represent 35% of US FDA approvals. When marketing treatmen...
Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetic industr...
Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals have reported positive Phase 2a data for vortosiran, an...
The Chinese University of Hong Kong (CUHK); the People’s Government of Nansha District, Guangzhou; and Guangzhou F...
Alebund Pharmaceuticals has randomised and dosed the first participant in its global Phase IIb multi-regional clinical t...
ING has examined the shifting global pharmaceutical landscape in a podcast discussion focused on China’s biotech b...
Akeso has dosed the first patient in a Phase II clinical study evaluating AK146D1 in combination with ivonescimab for ad...
Fangzhou Inc. has announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination ...
Innovent Biologics and Spero Therapeutics have entered into an exclusive licence agreement for IBI355, also known as SP0...
Menarini Asia-Pacific has announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distri...
AstraZeneca has entered into an exclusive license agreement with China-based Dizal Pharmaceutical for Zegfrovy ...
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration for ...
